What is Creso Pharma?
Headquartered in Nedlands, Australia, Creso Pharma Limited is a specialized developer and commercializer of pharmaceutical-grade cannabis and hemp-based nutraceuticals. The company operates a diversified business model that spans human therapeutic products and animal health solutions. Its core portfolio includes innovative offerings such as anibidiol, a feed supplement for companion animals, and cannaQIX, a stress-reducing nutraceutical enriched with vitamins and zinc. By integrating rigorous scientific standards with natural extract technology, Creso Pharma addresses critical gaps in the wellness and veterinary markets. The firm's commitment to quality control and regulatory compliance has established it as a key player in the global cannabis ecosystem, facilitating its expansion into diverse geographic territories.
How much funding has Creso Pharma raised?
Creso Pharma has raised a total of $9M across 1 funding round:
Other Financing Round
$9M
Other Financing Round (2020): $9M with participation from Adam Blumenthal
Key Investors in Creso Pharma
Adam Blumenthal
A strategic investor and key stakeholder with a focus on the pharmaceutical and life sciences sectors, providing essential capital to support Creso Pharma's growth initiatives.
What's next for Creso Pharma?
Looking ahead, the recent capital allocation is expected to catalyze the commercialization of Creso Pharma's existing product suite while funding the development of new therapeutic applications. The company is likely to prioritize scaling its distribution networks in North America and the Asia Pacific, where demand for high-quality hemp-derived products is rising. Furthermore, the strategic focus will likely shift toward optimizing supply chain efficiencies and deepening its research into CBD-based topical treatments like cannaDOL. As the regulatory environment for cannabis-based medicine continues to mature, Creso Pharma is strategically positioned to leverage its intellectual property and established market presence to drive long-term shareholder value and operational growth.
See full Creso Pharma company page
